Patents by Inventor Samedy Ouk

Samedy Ouk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210171466
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 10, 2021
    Inventors: Samedy OUK, Esmir GUNIC, Jean-Michel VERNIER, Chixu CHEN
  • Publication number: 20210121450
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: November 9, 2020
    Publication date: April 29, 2021
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Patent number: 10919858
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: February 16, 2021
    Assignee: Ardea Biosciences, Inc
    Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen
  • Patent number: 10857139
    Abstract: Provided herein are compounds and pharmaceutical compositions including the compound having a formula: These compounds are androgen receptor modulators useful for the treatment of androgen receptor-associated conditions.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: December 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Publication number: 20200345739
    Abstract: The present invention provides, inter alia, compounds capable of inhibiting NF-?B. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
    Type: Application
    Filed: April 27, 2020
    Publication date: November 5, 2020
    Inventors: Samedy Ouk, Hsiou-Chi Liou
  • Patent number: 10660894
    Abstract: The present invention provides, inter alia, compounds capable of inhibiting NF-?B. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: May 26, 2020
    Assignee: ImmuneTarget, Inc.
    Inventors: Samedy Ouk, Hsiou-Chi Liou
  • Publication number: 20200079741
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: July 17, 2019
    Publication date: March 12, 2020
    Applicant: The Regents of the University of California
    Inventors: Charles L. SAWYERS, Michael JUNG, Charlie D. CHEN, Samedy OUK, Derek WELSBIE, Chris TRAN, John WONGVIPAT, Dongwon YOO
  • Publication number: 20190314377
    Abstract: The disclosure relates to compounds and compositions that inhibit NF-?B and are useful in the treatment of hematological malignancies such as lymphoma and myeloma.
    Type: Application
    Filed: June 26, 2019
    Publication date: October 17, 2019
    Inventors: Johannes ZAKRZEWSKI, Hsiou-Chi LIOU, Samedy OUK
  • Publication number: 20190210974
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 11, 2019
    Applicant: The Regents of the University of California
    Inventors: Charles L. SAWYERS, Michael JUNG, Charlie D. CHEN, Samedy OUK, Derek WELSBIE, Chris TRAN, John WONGVIPAT, Dongwon YOO
  • Publication number: 20190185431
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Application
    Filed: November 14, 2018
    Publication date: June 20, 2019
    Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen
  • Publication number: 20190142836
    Abstract: The present invention provides, inter alia, compounds capable of inhibiting NF-?B. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 16, 2019
    Inventors: Samedy Ouk, Hsiou-Chi Liou
  • Patent number: 10266493
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: April 23, 2019
    Assignee: Ardea Biosciences, Inc.
    Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen
  • Patent number: 10226464
    Abstract: The present invention provides, inter alia, compounds capable of inhibiting NF-?B. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: March 12, 2019
    Assignee: ImmuneTarget, Inc.
    Inventors: Samedy Ouk, Hsiou-Chi Liou
  • Publication number: 20190000851
    Abstract: The present invention provides, inter alia, compounds capable of inhibiting NF-?B. Pharmaceutical compositions containing and methods of using the compounds are also provided herein. Also provided are methods and kits for treating cancer and solid tumors in a subject, as well as methods and kits for inducing cancer cell death and apoptosis of a cancer cell, all utilizing the NF-?B inhibitors described herein.
    Type: Application
    Filed: June 27, 2018
    Publication date: January 3, 2019
    Inventors: Samedy Ouk, Hsiou-Chi Liou
  • Publication number: 20180318276
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: May 2, 2018
    Publication date: November 8, 2018
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Patent number: 9987261
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: June 5, 2018
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Publication number: 20180086718
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: July 20, 2017
    Publication date: March 29, 2018
    Applicant: The Regents of the University of California
    Inventors: Charles L. Sawyers, Michael Jung, Charlie D. Chen, Samedy Ouk, Derek Welsbie, Chris Tran, John Wongvipat, Dongwon Yoo
  • Patent number: 9873674
    Abstract: Compounds having a c-Rel inhibiting property according to the formula: (1) wherein R1 and R2 are each independently selected from hydrogen atom and hydrocarbon groups having at least one and up to thirty carbon atoms and optionally substituted with one or more heteroatoms selected from halogen, nitrogen, oxygen, and sulfur; R3 is selected from hydrocarbon groups having at least one and up to thirty carbon atoms and optionally substituted with one or more heteroatoms selected from halogen, nitrogen, oxygen, and sulfur; and X1, X2, and X3 are each independently selected from oxygen and sulfur atoms. Methods for treating diseases and conditions associated with c-Rel overexpression by administering compounds of Formula (1) or a pharmaceutical composition thereof to a subject afflicted with such a disease or condition are also described.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: January 23, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Hsiou-Chi Liou, Mei-Ling Liou, Samedy Ouk
  • Publication number: 20170182051
    Abstract: The present invention provides, inter alia, compounds capable of inhibiting NF-?B. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
    Type: Application
    Filed: December 29, 2016
    Publication date: June 29, 2017
    Inventors: Samedy Ouk, Hsiou-Chi Liou
  • Publication number: 20170014399
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: June 13, 2016
    Publication date: January 19, 2017
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat